Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Acquire Arena Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Tickers ARNA PFE
News headline image
Pfizer Declares First-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Provide Update on Omicron Variant
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Completes Acquisition of Trillium Therapeutics
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.